The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.
Alexander E. Drilon
No relevant relationships to disclose
Lu Wang
No relevant relationships to disclose
Maria E. Arcila
No relevant relationships to disclose
Eun Jung Cho
No relevant relationships to disclose
Sohail Balasubramanian
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Joel R. Greenbowe
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Jeffrey S. Ross
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Phil Stephens
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Doron Lipson
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Vincent A. Miller
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Mark G. Kris
No relevant relationships to disclose
Marc Ladanyi
Stock Ownership - Foundation Medicine
Naiyer A. Rizvi
No relevant relationships to disclose